Evaxion reports sustained responses at three-year follow-up in EVX-01 phase 2 melanoma trial
EVAX•Evaxion reported no tumor progression at three-year follow-up in all evaluated advanced melanoma patients receiving its personalized cancer vaccine EVX-01. Patients received EVX-01 alone during the third treatment year; new clinical and immune findings are scheduled for presentation October 24, 2026, at the ESMO Congress in Madrid.
1. Three-year follow-up
Evaxion reported sustained responses without tumor progression at three-year follow-up in all evaluated advanced melanoma patients receiving EVX-01. Patients received the personalized cancer vaccine alone during the third treatment year, extending clinical benefits previously reported at two-year follow-up.
2. Findings presentation
New clinical and immune findings will be presented October 24, 2026, at the ESMO Congress in Madrid.
